Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM
TipRanks (Wed, 25-Mar 6:33 AM ET)
Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders
Globe Newswire (Tue, 10-Feb 8:30 AM ET)
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.
Zhengye Biotechnology Holding Limited - trades on the NASDAQ stock market under the symbol ZYBT.
As of March 24, 2026, ZYBT stock price declined to $0.87 with 194,898 million shares trading.
ZYBT has a beta of -0.08, meaning it tends to be less sensitive to market movements. ZYBT has a correlation of 0.00 to the broad based SPY ETF.
ZYBT has a market cap of $41.21 million. This is considered a Sub-Micro Cap stock.
ZYBT has underperformed the market in the last year with a return of -85.0%, while the SPY ETF gained +15.1%. In the last 3 month period, ZYBT fell short of the market, returning -48.2%, while SPY returned -5.1%. However, in the most recent 2 weeks ZYBT has outperformed the stock market by returning +11.3%, while SPY returned -3.3%.
ZYBT support price is $.86 and resistance is $1.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYBT shares will trade within this expected range on the day.